A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Advances in Therapy Pub Date : 2024-09-18 DOI:10.1007/s12325-024-02987-7

Fengkui Zhang, Aizong Shen, Waqas Ahmed, Richard F. Pollock

{"title":"A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China","authors":"Fengkui Zhang, Aizong Shen, Waqas Ahmed, Richard F. Pollock","doi":"10.1007/s12325-024-02987-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Intravenous (IV) iron is the recommended treatment for patients with iron deficiency anemia (IDA) unresponsive to oral iron treatment, in whom oral iron is contraindicated, or where rapid iron replenishment is required. Ferric derisomaltose (FDI) and ferric carboxymaltose (FCM) are high-dose, rapid-infusion, IV iron formulations that have recently been compared in three head-to-head randomized controlled trials (RCTs), which showed significantly higher incidence of hypophosphatemia after administration of FCM than FDI. The present study objective was to evaluate the cost–utility of FDI versus FCM in a population of patients with IDA in China.</p><h3>Methods</h3><p>A previously-published patient-level simulation model was used to model the cost–utility of FDI versus FCM in China. The number of infusions of FDI and FCM was modeled based on the approved posology of the respective formulations using simplified tables of iron need in a population of patients with body weight and hemoglobin levels informed by a Chinese RCT of FCM. Data on the incidence of hypophosphatemia was obtained from the PHOSPHARE-IDA RCT, while data on disease-related quality of life were obtained from SF-36v2 data from the PHOSPHARE-IBD RCT.</p><h3>Results</h3><p>Over the 5-year time horizon, patients received 3.98 courses of iron treatment on average, requiring 0.90 fewer infusions of FDI than FCM (7.69 vs. 6.79). This resulted in iron procurement and administration cost savings of renminbi (RMB) 206 with FDI (RMB 3,519 vs. RMB 3,312). Reduced incidence of hypophosphatemia-related fatigue resulted in an increase of 0.07 quality-adjusted life years and further cost savings of RMB 782 over 5 years, driven by reduced need for phosphate testing and replenishment. FDI was therefore the dominant intervention.</p><h3>Conclusions</h3><p>The results showed that FDI would improve patient quality of life and reduce direct healthcare expenditure versus FCM in patients with IDA in China.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"41 11","pages":"4191 - 4204"},"PeriodicalIF":3.4000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-024-02987-7.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-024-02987-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Intravenous (IV) iron is the recommended treatment for patients with iron deficiency anemia (IDA) unresponsive to oral iron treatment, in whom oral iron is contraindicated, or where rapid iron replenishment is required. Ferric derisomaltose (FDI) and ferric carboxymaltose (FCM) are high-dose, rapid-infusion, IV iron formulations that have recently been compared in three head-to-head randomized controlled trials (RCTs), which showed significantly higher incidence of hypophosphatemia after administration of FCM than FDI. The present study objective was to evaluate the cost–utility of FDI versus FCM in a population of patients with IDA in China.

Methods

A previously-published patient-level simulation model was used to model the cost–utility of FDI versus FCM in China. The number of infusions of FDI and FCM was modeled based on the approved posology of the respective formulations using simplified tables of iron need in a population of patients with body weight and hemoglobin levels informed by a Chinese RCT of FCM. Data on the incidence of hypophosphatemia was obtained from the PHOSPHARE-IDA RCT, while data on disease-related quality of life were obtained from SF-36v2 data from the PHOSPHARE-IBD RCT.

Results

Over the 5-year time horizon, patients received 3.98 courses of iron treatment on average, requiring 0.90 fewer infusions of FDI than FCM (7.69 vs. 6.79). This resulted in iron procurement and administration cost savings of renminbi (RMB) 206 with FDI (RMB 3,519 vs. RMB 3,312). Reduced incidence of hypophosphatemia-related fatigue resulted in an increase of 0.07 quality-adjusted life years and further cost savings of RMB 782 over 5 years, driven by reduced need for phosphate testing and replenishment. FDI was therefore the dominant intervention.

Conclusions

The results showed that FDI would improve patient quality of life and reduce direct healthcare expenditure versus FCM in patients with IDA in China.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国缺铁性贫血患者服用地异麦芽糖铁与羧甲基麦芽糖铁的成本效用分析

导言对于口服铁剂治疗无效、口服铁剂有禁忌症或需要快速补充铁剂的缺铁性贫血（IDA）患者，静脉注射（IV）铁剂是推荐的治疗方法。二异麦芽糖铁（FDI）和羧甲基麦芽糖铁（FCM）是高剂量、快速输注的静脉注射铁制剂，最近在三项头对头随机对照试验（RCT）中对这两种制剂进行了比较，结果显示服用 FCM 后低磷血症的发生率明显高于 FDI。本研究的目的是评估 FDI 与 FCM 在中国 IDA 患者群体中的成本效用。方法：使用之前发表的患者水平模拟模型来模拟 FDI 与 FCM 在中国的成本效用。根据 FCM 的中国 RCT 所提供的患者体重和血红蛋白水平，使用简化的铁需要量表，根据 FDI 和 FCM 的批准药方，模拟 FDI 和 FCM 的输注次数。低磷血症发病率的数据来自 PHOSPHARE-IDA RCT，而与疾病相关的生活质量数据则来自 PHOSPHARE-IBD RCT 的 SF-36v2 数据。结果在 5 年的时间跨度内，患者平均接受了 3.98 个疗程的铁剂治疗，所需的 FDI 输注次数比 FCM 少 0.90 次（7.69 次对 6.79 次）。与 FDI 相比，铁剂采购和管理成本节省了 206 元人民币（3519 元人民币对 3312 元人民币）。由于减少了磷酸盐检测和补充的需求，与低磷血症相关的疲劳发生率降低，质量调整生命年增加了 0.07 年，5 年内进一步节省了 782 元人民币的成本。结论结果表明，与全血细胞生成素治疗相比，全血细胞生成素治疗可提高中国 IDA 患者的生活质量，减少直接医疗支出。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.